-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Farletuzumab Ecteribulin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Farletuzumab Ecteribulin in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Farletuzumab Ecteribulin in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MuSK-CAART in Myasthenia Gravis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MuSK-CAART in Myasthenia Gravis Drug Details:MuSK-CAART is under development for the treatment of B-cell mediated autoimmune...
-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RGV-004 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RGV-004 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RGV-004 in Follicular Lymphoma Drug Details: RGV-004 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rozanolixizumab in Fibromyalgia (Fibromyalgia Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rozanolixizumab in Fibromyalgia (Fibromyalgia Syndrome) Drug Details: Rozanolixizumab (Rystiggo) acts as an anti inflammatory agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rozanolixizumab in Demyelinating Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rozanolixizumab in Demyelinating Diseases report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rozanolixizumab in Demyelinating Diseases Drug Details: Rozanolixizumab (Rystiggo) acts as an anti...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pomalidomide in Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pomalidomide in Amyloidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pomalidomide in Amyloidosis Drug Details: Pomalidomide (Pomalyst / Imnovid) is a derivative of...
-
Company Profile
Avon Products Inc – Company Profile
Avon Products Inc (Avon), a subsidiary of Natura & Co Holding SA, manufactures and markets beauty products. The company’s product portfolio includes skin and hair care products, fragrances, jewelry, watches, apparel, footwear, accessories, gift and decorative products, homeware, entertainment and leisure products, children's products, nutritional products, and cosmetics. It markets these products under various brands, including Anew, Avon Care, Avon True. Avon Eve, Avon Naturals, Clearskin, Musk Marine, and Advance Techniques. The company sells these products through drug stores and...
Add to Basket -
Company Bundle
Bundle: Elon Musk Portfolio Companies
Gain a 360-degree view of the Technology theme and make more informed decisions for your business. Bundle: Elon Musk Portfolio Companies bundle is a cost-effective solution as it provides access to multiple Company Profiles at a discounted price. Access exclusive data from a trusted intelligence provider with decades of experience serving the most successful companies in the world.
Add to Basket